135 related articles for article (PubMed ID: 37927289)
21. New and old biomarkers in the differential diagnosis of lung cancer: Pro-gastrin-releasing peptide in comparison with neuron-specific enolase, carcinoembryonic antigen, and CYFRA 21-1.
Mauro C; Passerini R; Spaggiari L; Galetta D; Radice D; Lentati P; Sandri MT
Int J Biol Markers; 2019 Jun; 34(2):163-167. PubMed ID: 30994045
[TBL] [Abstract][Full Text] [Related]
22. [Tumor markers in pleural effusion of patients with lung cancer and patients with tuberculous pleurisy].
Tada A; Kawai H; Matsumoto H; Kimura G; Okada C; Soda R; Takahashi K
Nihon Kokyuki Gakkai Zasshi; 2002 Feb; 40(2):106-12. PubMed ID: 11974864
[TBL] [Abstract][Full Text] [Related]
23. History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer.
Nakamura H; Nishimura T
Surg Today; 2017 Sep; 47(9):1037-1059. PubMed ID: 28229299
[TBL] [Abstract][Full Text] [Related]
24. [Clinical Significance of Tumor Marker Detection in Patients
with Advanced Squamous Cell Carcimoma of the Lung].
Liang P; Li J
Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):641-647. PubMed ID: 27760591
[TBL] [Abstract][Full Text] [Related]
25. [Diagnostic values of conventional tumor markers and their combination with chest CT for patients with stageⅠA lung cancer].
Peng Q; Wu N; Huang Y; Zhao SJ; Tang W; Liang M; Ran YL; Xiao T; Yang L; Liang X
Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):934-941. PubMed ID: 37968078
[No Abstract] [Full Text] [Related]
26. [Value of tumor markers series of hydrothorax in differential diagnosis of pleural effusion].
Liu YQ; Zhang HL; Gao WJ; Lan X; Yuan BJ; Zou JM
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2008 Jan; 26(1):34-8. PubMed ID: 18302890
[TBL] [Abstract][Full Text] [Related]
27. The Serum Tumor Markers in Combination for Clinical Diagnosis of Lung Cancer.
Wu H; Wang Q; Liu Q; Zhang Q; Huang Q; Yu Z
Clin Lab; 2020 Mar; 66(3):. PubMed ID: 32162867
[TBL] [Abstract][Full Text] [Related]
28. Clinical observations on the association between diagnosis of lung cancer and serum tumor markers in combination.
Wang WJ; Tao Z; Gu W; Sun LH
Asian Pac J Cancer Prev; 2013; 14(7):4369-71. PubMed ID: 23992005
[TBL] [Abstract][Full Text] [Related]
29. [Tumor markers in lung cancer].
Niho S; Shinkai T
Gan To Kagaku Ryoho; 2001 Dec; 28(13):2089-93. PubMed ID: 11791391
[TBL] [Abstract][Full Text] [Related]
30. Biomarkers in the lung cancer diagnosis: a clinical perspective.
Li X; Asmitananda T; Gao L; Gai D; Song Z; Zhang Y; Ren H; Yang T; Chen T; Chen M
Neoplasma; 2012; 59(5):500-7. PubMed ID: 22668014
[TBL] [Abstract][Full Text] [Related]
31. Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers.
Akita T; Ariyasu R; Kakuto S; Miyadera K; Kiritani A; Tsugitomi R; Amino Y; Uchibori K; Kitazono S; Yanagitani N; Tasaka S; Nishio M
Thorac Cancer; 2024 Apr; 15(10):788-796. PubMed ID: 38400801
[TBL] [Abstract][Full Text] [Related]
32. [Usefulness and limitation of serum tumor markers in diagnosis of lung cancer].
Fukuda M; Oka M
Nihon Rinsho; 1996 Jun; 54(6):1610-5. PubMed ID: 8691617
[TBL] [Abstract][Full Text] [Related]
33. Neuron-Specific Enolase Is an Independent Prognostic Factor in Resected Lung Adenocarcinoma Patients with Anaplastic Lymphoma Kinase Gene Rearrangements.
Li S; Cao L; Wang X; Wang F; Wang L; Jiang R
Med Sci Monit; 2019 Jan; 25():675-690. PubMed ID: 30673691
[TBL] [Abstract][Full Text] [Related]
34. Improvement of differential diagnosis of lung cancer by use of multiple protein tumor marker combinations.
Trulson I; Klawonn F; von Pawel J; Holdenrieder S
Tumour Biol; 2024; 46(s1):S81-S98. PubMed ID: 38277317
[TBL] [Abstract][Full Text] [Related]
35. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
[TBL] [Abstract][Full Text] [Related]
36. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E
Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
[TBL] [Abstract][Full Text] [Related]
37. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.
Dal Bello MG; Filiberti RA; Alama A; Orengo AM; Mussap M; Coco S; Vanni I; Boccardo S; Rijavec E; Genova C; Biello F; Barletta G; Rossi G; Tagliamento M; Maggioni C; Grossi F
J Transl Med; 2019 Mar; 17(1):74. PubMed ID: 30849967
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of blood-based protein biomarkers in non-small cell lung cancer: A critical review and 2008-2022 update.
Trulson I; Holdenrieder S
Tumour Biol; 2024; 46(s1):S111-S161. PubMed ID: 37927288
[TBL] [Abstract][Full Text] [Related]
39. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer.
Holdenrieder S; von Pawel J; Dankelmann E; Duell T; Faderl B; Markus A; Siakavara M; Wagner H; Feldmann K; Hoffmann H; Raith H; Nagel D; Stieber P
Clin Cancer Res; 2008 Dec; 14(23):7813-21. PubMed ID: 19047109
[TBL] [Abstract][Full Text] [Related]
40. Serum levels of five tumor markers for lung cancer in patients with chronic renal failure.
Nomura F; Koyama A; Ishijima M; Takano S; Narita M; Nakai T
Oncol Rep; 1998; 5(2):389-92. PubMed ID: 9468564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]